Skip to main content
. 2019 May 7;11:4109–4118. doi: 10.2147/CMAR.S190098

Figure 4.

Figure 4

The comparison of SAEs in two generations ALK inhibitors.

Notes: (A) pneumonia; (B) dyspnoea and respiratory failure; (C) pleural effusion; (D) thrombotic disease; (E) pyrexia; (F) vomiting; (G) nausea.

Abbreviation: ALK, Anaplastic lymphoma kinase.